NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA) announced today the launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of SIGA-246, its lead smallpox drug. The study will examine the safety and pharmacokinetics of SIGA-246 at three different dosages in healthy volunteers when taken once a day for 21 days.
